Find a Trial

Trial Results


12 protocol(s) meet the specified criteria
207497OPEN TO ACCRUAL
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma DREAMM-6
CTO-208887OPEN TO ACCRUAL
A Phase I/II Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM5
CTO-64007957MMY1004OPEN TO ACCRUAL
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma
CTO-CAEL101-301OPEN TO ACCRUAL
CTO-CAEL101-302OPEN TO ACCRUAL
CTO-IUSCC-0729OPEN TO ACCRUAL
Non-coding mutations in Multiple Myeloma
CTO-R5458-ONC-1826OPEN TO ACCRUAL
A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
CTO-TAK-981-1503OPEN TO ACCRUAL
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUSCC-0633OPEN TO ACCRUAL
Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery
IUSCC-0661OPEN TO ACCRUAL
The Indiana Myeloma Registry
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer